Efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir+ Dasabuvir and Ribavirin in patients with compensated HCV cirrhosis
Journal Title: Revista de Medicină Militară - Year 2019, Vol 0, Issue 1
Abstract
Background and aim: Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir in association with ribavirin was the only interferon-free regimen available in 2015 in Romania for compensated HCV cirrhosis. The aim of our study is to reveal our experience with interferon-free therapy in compensated HCV cirrhosis. Materials and methods: We conducted a multicenter prospective study including 90 patients with compensated (Child-Pugh A) HCV cirrhosis treated with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir and Ribavirin regimen for twelve weeks. The HCV infection was diagnosed using clinical, biological, and FibroMax tests. Each patient had follow-up visits at four, eight, twelve and twenty-four weeks after the initiation of the treatment. Results: 44 (49% of) patients were female and 46 (51 % of) were male. The mean age of patients in the study was 61 years old. All the patients had HCV genotype 1b infection. 22 patients were naive and 68 had previous antiviral therapies based on pegylated IFN-α and ribavirin. At the initiation of treatment 64 (71%) of patients had cytolysis, 38 (42%) had thrombocytopenia, 19 (21%) patients had hyperbilirubinemia and 11 (12%) patients had anemia. It was noticed a decreasing of cytolysis, only 10% of 64 patients still having cytolysis after four weeks of treatment. One patient (1%) died after four weeks of treatment by complications of cirrhosis. 89 (99%) of patients had a virologic response (VR) at the end of treatment (EOT) and sustained virologic response (SVR) twelve weeks after the last dose administration. Conclusion: The most common side effect among the patients in the study group was anemia (47% cases). Cytolysis disappeared after four weeks of treatment in 61% of patients. The interferon-free combination treatment was safe and highly effective in compensated HCV cirrhosis.
Authors and Affiliations
Georgiana Crisu, Florentina Ionita Radu, Raluca S. Costache, Vasile Balaban, Petrut Nuta, Victor Stoica, Oana Vutcan, Ion Stefan, Florica Naftanaila Mali, Mariana Jinga
Keywords
Related Articles
- EP ID EP481289
- DOI -
- Views 83
- Downloads 0
Primary thyroid lymphoma – case report
Introduction. Even though, primary thyroid lymphoma (PTL) is a rare thyroid malignancy and extranodal non-Hodgkin lymphoma, this type of disease should not be disgraced in order to achieve an early diagnosis and multimo...
The semi-centenary of a prestigious medical unit: Military-Medical Research Center
The Military Medical Research Center (CCSMM) is a health research unit, subordinated to the Medical Directorate of the Ministry of National Defence. The overall objective is represented by conducting researches on the me...
Modern medicine has a new technology: Therapeutic electroporation
Electroporation is considered a new start-up in the treatment of various tumors; currently, researches are being conducted in order to develop this technology with medical applications. The technique consists in the sign...
Therapeutic management of schizophrenia and substance use disorders dual diagnosis – clinical vignettes
Patients with schizophrenia are frequently diagnosed with addictive comorbidities, and data in the literature support a 10 to 70% prevalence of this dual diagnosis. Nonetheless, substance use disorders can be missed duri...
The strategic importance of vaccination for national defense and security
Public health is the most important power factor of a nation, from which all other factors derive. Infectious diseases are the most important cause of morbidity and mortality in humans. Vaccination is the most important...